Hypereosinophilic Syndrome Following the BNT162b2 (BioNTech/Pfizer) Vaccine Successfully Treated with Mepolizumab: A Case Report and Review of the Literature

Although an increasing number of real-life data confirm large-scale clinical trial findings on the efficacy and safety of SARS-CoV-2 vaccines, rare but severe adverse reactions have begun to emerge. Here, we report a full-blown hypereosinophilic syndrome (HES) following a BNT162b2 (BioNTech/Pfizer)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoxha, Ariela, Tomaselli, Tania, Minicucci, Giacomo Maria, Dall’Acqua, Jacopo, Zardo, Davide, Simioni, Paolo, Naldi, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051530/
https://www.ncbi.nlm.nih.gov/pubmed/36983376
http://dx.doi.org/10.3390/jcm12062376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051530/
https://www.ncbi.nlm.nih.gov/pubmed/36983376
http://dx.doi.org/10.3390/jcm12062376

Ejemplares similares